Antimuscarinic drugs to treat overactive bladder

BMJ (Online)

Volumn 344, Issue 7852, 2012, Pages

  Robinson, Dudley ^a   Cardozo, Linda ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIRETROVIRUS AGENT; CYTOCHROME P450; DARIFENACIN; DESMOPRESSIN; DOMPERIDONE; FESOTERODINE; HALOPERIDOL; ITRACONAZOLE; KETOCONAZOLE; LEVODOPA; METOCLOPRAMIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PHENOTHIAZINE DERIVATIVE; PLACEBO; PROPIVERINE; SOLIFENACIN; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT; TROSPIUM CHLORIDE; VASOPRESSIN;

ADULT; ARTICLE; BLURRED VISION; CASE REPORT; CLINICAL EFFECTIVENESS; COGNITIVE DEFECT; CONSERVATIVE TREATMENT; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIZZINESS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; HEART INJURY; HUMAN; KIDNEY FUNCTION; KIDNEY METABOLISM; LIVER FUNCTION; LIVER METABOLISM; MALE; MICTURITION DISORDER; NOCTURIA; NOCTURNAL ENURESIS; OVERACTIVE BLADDER; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT MONITORING; POSTVOID RESIDUAL URINE VOLUME; PREGNANCY; PRIORITY JOURNAL; QT PROLONGATION; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SOMNOLENCE; TREATMENT DURATION; URINE INCONTINENCE; XEROSTOMIA; DRUG EFFECT; FEMALE; MIDDLE AGED; PATHOPHYSIOLOGY; URODYNAMICS;

FEMALE; HUMANS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; QUALITY OF LIFE; URINARY BLADDER, OVERACTIVE; URODYNAMICS;

EID: 84859712184     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e2130     Document Type: Article

References (31)

1. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynaecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 2010;21:5-26.
2. Stewart WF, Corey R, Herzog AR, Wein A, Norton PA, Payne C, et al. Prevalence of overactive bladder in women: results from the NOBLE program. Int Urogynaecol J 2001;12:S66.
3. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-6. (Pubitemid 34204313)
4. Sibley GN. Developments in our understanding of overactive bladder. Br J Urol 1997;80:54-61.
5. Brading AF A myogenic basis for the overactive bladder. Urology 1997;50:57-67.
6. Hashim H, Abrams P. Do symptoms of overactive bladder predict urodynamic detrusor overactivity? Neurorol Urodyn 2004;23:484.
7. Andersson KE, Chapple CR, Cardozo L, Cruz F, Hashim H, Michel MC, et al. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence. 4th ed. Health Publication, 2009:631-700.
8. Hadorn DC, Baker D, Hodges JS, Hicks N. Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol 1996;49:749-54. (Pubitemid 26280725)
9. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001;323:334-6. (Pubitemid 32744465)
10. Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared to placebo in the treatment of overactive bladder: systematic review. BMJ 2003;326:841-4. (Pubitemid 36461413)
11. Nabi G, Cody JD, Ellis G, Hay-Smith J, Herbison GP. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006;(4):CD003781.
12. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543-62.
13. Appell RA, Sand P, Dmochowski R, Anderson R, Zinner N, Lama D, et al for the Overactive Bladder Judging Effective Control and Treatment Study Group. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001;76:358-63. (Pubitemid 32248750)
14. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A, Tolterodine Study Group. Tolterodine once daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001;57:414-21. (Pubitemid 32192963)
15. Diokno AC, Appell RA, Sand PK, Dmochowski RR, GburekBM, Klimberg IW, et al OPERA Stuy Group. Prospective, randomised, double blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003;78:687-95. (Pubitemid 36665898)
16. Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, et al, for the STAR study group. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70. (Pubitemid 41188406)
17. Herschorn S, Swift S, Guan Z, Carlsson M, Morrow J, Brodsky M, et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head to head placebo controlled trial. BJU Int 2009;105:58-66.
18. Sexton CC, Notte SM, Maroulis C, Dmochowski RR, Cardozo L, Subramanian D, et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract 2011;65:567-85.
19. Oefelein MG. Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder. Drug Saf 2011;34:733-54.
20. Paquette A, Gou P, Tannenbaum C. Systematic review and meta-analysis; do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? J Am Geriatr Soc 2011;59:1332-9.
21. Wesnes KA, Edgar C, Tretter RN, Bolodeoku J. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin. Expert Opin Drug Saf 2009;8:615-26.
22. Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract 2008;62:1792-800.
23. Staskin D, Kay G, Tannebaum C, Goldman HB, Bhashi K, Ling J, et al. Trospium choride has no effect on memory testing and is assay undectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract 2010;64:1294-300.
24. Cardozo L, Thorpe A, Warner J, Sidhu M. The cost effectiveness of solifenacin vs fesoterodine, oxybutynin immediate release, propiverine, tolterodine extended release and tolterodine immediate release in the treatment of patients with overactive bladder in the UK National Health Service. BJU Int 2010;106:506-14.
25. Speakman M, Khullar V, Mundy A, Odeyemi I, Bolodeoku J. A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. Curr Med Res Opin 2008;24:2173-9.
26. Alhasso AA, McKinlay J, Patrick K, Stewart L. Anticholinergic drugs versus non drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006;(4):CD003193.
27. Laval KU, Lutzeyer W. Spontaneous phasic activity of the detrusor: a cause of uninhibited contractions in unstable bladder. Urol Int 1980;35:182-7. (Pubitemid 10153587)
28. Chapple C, Patroneva A, Raines S. Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: a randomized double-blind placebo controlled study (ZD0947IL/0004). Eur Urol 2006;49:879-86.
29. Green SA, Alon A, Ianus J, McNaughton, Tozzi CA, Reiss TF. Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence. J Urol 2006;176:2535-40. (Pubitemid 44665982)
30. Colli E, Digesu GA, Olivieri L. Overactive bladder treatments in early phase clinical trials. Expert Opin Investig Drugs 2007;16:999-1007. (Pubitemid 47078776)
31. Chapple CR, Yamaguchi O, Ridder A. Clinical proof of concept study (Blossom) shows novel β3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder. Eur Urol Suppl 2008;7:239.